Role of protocol biopsy in early graft dysfunction in renal transplant recipient.

: This study was designed to evaluate the role of protocol biopsy in renal allograft recipients. A total of thirty five kidney transplant recipients with a mean age of 35±5 years included in this study. Mean age of donor was 41±8 years. The study was performed from April 2008 to November 2009 in the Department of Nephrology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. Immunosuppressive protocol used for transplant patient was, Cyclosporine 8mg/kg/day, Mycophenolate mofetil (MMF) 500mg twice daily, Prednisolone 0.5mg/kg/day. Protocol biopsy done on day 0 (Peroperative), day 14 and day 90. Stains used H&E and PAS. Cyclosporine blood level was done on 7th and 14th postoperative day and monthly for 3 months. Serum creatinine was done daily for 14 days & then weekly upto 3 months. Among 35 patients 23(66%) showed normal graft function and 12(34%) early graft dysfunction. Aetiology of early graft dysfunction includes 50% clinical rejection, 17% acute tubular necrosis (ATN), 17% cyclosporine toxicity, 8% graft thrombosis and 8% recurrence of GN. Per operative protocol biopsy showed normal histology in 28(80%) cases, in 4 cases 11% glomeruli showed sclerosis and in 3 cases 9% glomeruli showed sclerosis. At 14th post operative day 60% patients showed normal histology, 14% had clinical rejection (elevated serum creatinine along with histological features of rejection), another 14% had sub clinical rejections (normal serum creatinine with histological changes), cyclosporine toxicity 5.6%, ATN 5.6%, and recurrent glomerulonephritis in 3% cases. Among clinical rejection, according to Banff numerical classification, Grade-1 (20%), Grade-2 (60%), Grade-3 (20%) and among sub clinical rejections Banff Grade-1 (80%), Grade-2 (20%). Biopsy after 3 months showed normal histology 54.28%, clinical rejection 11.42%, sub clinical rejection 5.7%, borderline change 5.7%, cyclosporine toxicity 5.7% & 2.8% recurrent glomerulonephritis. According to Banff numerical classification in clinical rejection Banff Grade-1 (25%), Grade-2 (50%) and Grade-3 (25%). Among subclinical rejection Banff Grade-1 (70%), Grade-2 (30%).